Phaarmasia Ltd.
Snapshot View

32.70 +1.05 ▲3.3%

26 July 2021, 04:00:00 P.M.
Volume: 638

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.phaarmasia.com
Financial Indicators
Market Cap 21.61 Cr.
Earnings per share (EPS) 0.46 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 69.48 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 20.00 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.58 Calculated using Price: 31.65
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.68 Cr. 6,826,960 Shares
FaceValue 10
Company Profile

The company was incorporated on  February 6,1981 as Phaarmasia Private Limited, and the company was converted into a public limited company, Phaarmasia Limited on February 15, 1992, it is into manufacturing of pharmaceutical formulations. Company's facilities are spread over in 3 acres of land with built up area of 90,000 sq.ft.

The company was established for  carrying on the business as manufacturers, buyers, sellers, importers, exporters, distributors, agents and or otherwise deal as wholesalers, or retailers in drugs, medicines, pharmaceuticals, chemicals and other intermediates, dyes pigments, paints, rubber chemicals, phyto chemicals, hormones, agro-chemicals, veterinary and poultry products, food and nutritional products, house-hold remedies, biological and herbal products.

Phaarmasia’s registered office is located at 16,Phase III, I.D.A Jeedimetla, Hyderabad, Andhra Pradesh 500 055, India.

The company had restructured its Paid up Share Capital account of 91,34,800 Equity Shares of Rs 10 each fully paid up as on 31st, March,2005 by reducing / debiting the amount of Rs 730.78 lakhs for setting off the Accumulated Losses of the Company and has further allotted 50,00,000 Equity Shares of Rs 10each to promoters and Associates for Rs 250 lakhs and balance to Unsecured Creditors as approved in the above Scheme of Arrangement.

Product range of the company includes:

Phaarmasia’s product range includes amexine, angicare, flamfort, nasorel, flemkof, ginadox, medix and ziron. Its amexine is an antibiotic, which is used for upper respiratory tract infections, mucolytic and expectorant.

Company also provides nasorel PR, which is a therapeutic category that comes under antihistamine and sympathomimetic.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.32%
1 Week
-2.24%
1 Month
+2.51%
3 Month
+9.00%
6 Month
-2.97%
1 Year
+78.69%
2 Year
+57.59%
5 Year
+34.02%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 2.80 2.30 4.71 1.86 0.55 2.16 7.54 9.51 6.08
Return on Capital Employed (%) 7.25 3.13 6.12 5.28 3.35 3.63 9.32 10.35 11.07
Return on Assets (%) 0.85 0.73 1.86 0.86 0.22 0.85 2.76 2.82 1.61

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 8 8 7 13 12 12 12 13 13
Non Curr. Liab. 0 0 0 0 0 1 1 1 1
Curr. Liab. 16 17 6 6 6 7 9 20 19
Minority Int.
Equity & Liab. 24 25 13 19 19 20 22 33 34
Non Curr. Assets 12 11 11 16 14 14 14 14 14
Curr. Assets 12 13 3 3 4 6 8 19 20
Misc. Exp. not W/O
Total Assets 24 25 13 19 19 20 22 33 34

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 36 14 21 19 22 14 20 24 24
Other Income 0 0 0 1 1 1 1 1
Total Income 36 14 21 19 22 15 21 25 25
Total Expenditure -35 -13 -20 -18 -21 -14 -20 -23 -24
PBIDT 1 1 1 1 1 1 1 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 -1 -1 0 0 0 0
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items 0
PAT 0 0 0 0 0 0 1 1 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -2 0 0 0 0 0 1 0 0
Cash Fr. Inv. 0 0 0 0 0 0 -1 0
Cash Fr. Finan. 0 0 0 0 0 0 0
Net Change -2 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 73.45 73.45 73.45 73.45 73.45 73.51 73.45 73.51 73.51
Public 26.55 26.55 26.55 26.55 26.55 26.49 26.55 26.49 26.49
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 09 Jul 2021
Shareholding for the Period Ended June 30 2021
Phaarmasia Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 06 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 we are forwarding herewith a copy of the Certificate dated 5th July 2021 received from M/s. Venture Capital & Corporate Investments Pvt. Ltd Hyderabad 500018 the Registrar and Share Transfer Agent of the Company for the Quarter ended 30th June 2021.

Kindly take the same on record and acknowledge the receipt of the same.
Tue, 06 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- URVASHI BHATIA
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 703.40 +1.4%
Divi's Laboratories Ltd. 128,088.59 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,411.25 -0.2%
Cipla Ltd. 76,510.04 950.55 +0.3%
Cadila Healthcare Ltd. 62,965.29 605.55 -1.6%
Aurobindo Pharma Ltd. 56,484.48 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. 56,291.69 4,100.95 +4.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.81 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 4,100.95 +4.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.17 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 4,100.95 +4.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%